Journal of Clinical Oncology, Vol 13, 914-920, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma

M Harrison, D Tomlinson and S Stewart
Department of Oncology, St Mary's Hospital, London, United Kingdom.

PURPOSE: A phase II study was performed of single-agent liposomally entrapped doxorubicin ([LED] Doxil; Liposome Technology Inc, Menlo Park, CA) against locally advanced cutaneous/systemic AIDS-related Kaposi's sarcoma (KS). PATIENTS AND METHODS: Thirty-four patients with AIDS-related advanced cutaneous/systemic KS were treated with 20 mg/m2 of LED every 3 weeks on an outpatient basis. The median age was 39 years and the median Karnofsky score was 70. All patients had poor prognostic disease as judged by AIDS Clinical Trials Group (ACTG) criteria. Nineteen of 34 patients had received prior chemotherapy for KS, although no patient had received prior anthracyclines. RESULTS: An overall response rate of 73.5% (25 of 34) was observed. Partial responses (PRs) occurred in 67.7% (23 of 34) and complete responses (CRs) in 5.8% (two of 34). In patients who had received previous chemotherapy, the response rate was 68.4% (13 of 19), and all responses were PRs. The median time to response was 6 weeks. The median duration of response was 9 weeks. Toxicity according to World Health Organization (WHO) criteria was as follows: neutropenia (grade > or = 3), 34%; alopecia (grade 1 only), 9%; and nausea and vomiting (grade 1), 18%. One patient died of heart failure, which was not considered to be anthracycline-induced. CONCLUSION: LED appears to be highly active against AIDS-related KS. The major toxicity is neutropenia, which seems to be progressive in patients who receive several cycles of therapy. Comparative studies of LED versus conventional chemotherapy are needed.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. M. Moghimi, A. C. Hunter, and J. C. Murray Long-Circulating and Target-Specific Nanoparticles: Theory to Practice Pharmacol. Rev., June 1, 2001; 53(2): 283 - 318. [Abstract] [Full Text] [PDF]

				M. Lotem, A. Hubert, O. Lyass, M. A. Goldenhersh, A. Ingber, T. Peretz, and A. Gabizon Skin Toxic Effects of Polyethylene Glycol-Coated Liposomal Doxorubicin Arch Dermatol, December 1, 2000; 136(12): 1475 - 1480. [Abstract] [Full Text] [PDF]

				R. F. Little, K. M. Wyvill, J. M. Pluda, L. Welles, V. Marshall, W. D. Figg, F. M. Newcomb, G. Tosato, E. Feigal, S. M. Steinberg, et al. Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma J. Clin. Oncol., July 1, 2000; 18(13): 2593 - 2602. [Abstract] [Full Text] [PDF]

				E. T. M. Dams, P. Laverman, W. J. G. Oyen, G. Storm, G. L. Scherphof, J. W. M. van der Meer, F. H. M. Corstens, and O. C. Boerman Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1071 - 1079. [Abstract] [Full Text]

				D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744. [Abstract] [Full Text] [PDF]

				T. W. Cheung, S. C. Remick, N. Azarnia, J. A. Proper, J. R. Barrueco, and B. J. Dezube AIDS-related Kaposi's Sarcoma: A Phase II Study of Liposomal Doxorubicin Clin. Cancer Res., November 1, 1999; 5(11): 3432 - 3437. [Abstract] [Full Text] [PDF]

				J. Patel Liposomal doxorubicin: Doxil(R) Journal of Oncology Pharmacy Practice, December 1, 1996; 2(4): 201 - 210. [Abstract] [PDF]

				E. Tur, S. Brenner, M. Landau, and H. Golan Treatment of Kaposi's Sarcoma Arch Dermatol, March 1, 1996; 132(3): 327 - 331. [Abstract] [PDF]

				M. Harrison, D. Tomlinson, S. Stewart, and B. L. Zidar Periorbital Edema in Kaposi's Sarcoma N. Engl. J. Med., September 21, 1995; 333(12): 799 - 800. [Full Text]